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Abstract: Background: Pruritus is a well-recognized paraneoplastic phenomenon. Previous studies
have examined the association of itch with a variety of malignancies in adults. However, no large
study has examined this association in a pediatric population. Methods: A retrospective study
was conducted of patients age 18 or less seen at Johns Hopkins Health System between 2012 and
2019. Results: A pediatric hospital population of 1,042,976 patients was reviewed. Pruritus was
observed in 3836 pediatric patients of whom 130 also had cancer. Pediatric patients with pruritus were
significantly more likely to have concomitant malignancy compared to pediatric patients without
pruritus (OR 12.84; 95% CI 10.73–15.35, p < 0.001). Malignancies most strongly associated with
pruritus included neoplasms of the blood (OR 14.38; 95% CI 11.30–18.29, p < 0.001), bone (OR 29.02,
95% CI 18.28–46.06, p < 0.001) and skin (OR 22.76, 95% CI 9.14–56.72, p < 0.001. Conclusions: Pruritus
is significantly associated with malignancy in the pediatric hospital population. Clinicians should
also be aware of the high burden of itch in pediatric malignancies and the variation in pruritus
across malignancies.
Keywords: itch; pruritus; pediatric; children; malignancy; cancer; neoplasm; epidemiology

1. Introduction
Pruritus is a well-recognized phenomenon in cancer [1]. Previous studies have examined the
association of itch or pruritic dermatosis with a variety of malignancies in the adult population [2–5].
However, the pediatric population experiences significantly different ratios of malignancy types,
such as higher fractions of hematologic and nervous system related cancers [6,7]. We therefore expect
the association of pruritus and malignancy to be different in the pediatric population.
Sporadic case reports have presented pediatric patients with pruritus who upon investigation
were subsequently diagnosed with malignancies [8–12]. However, to our knowledge, no study has
examined the association of itch and cancer or the types of underlying cancers associated with itch in a
pediatric population. The objective of this study was therefore to examine the association of pruritus
and malignancy in pediatric patients at a USA tertiary care center.
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2. Materials and Methods
A retrospective study was conducted of pediatric patients seen at Johns Hopkins Health
System (JHHS), a U.S. tertiary care center which draws a diverse range of local, regional, national,
and international patients. The study population consisted of all patients age 18 or less seen at JHHS
between 1 January 2012 and 1 January 2019. Anonymized aggregate-level data was collected using the
Slicer Dicer function within Johns Hopkins EPIC electronic medical records [3–5,13,14]. IRB approval
was therefore waived. SNOMED-CT concept terms were used to specify all data [3–5,13,14]. All results
combined male and female patients.
2.1. Pediatric Pruritus Population
Using an EPIC Slicer Dicer, 3809 pediatric patients with a visit diagnosis, billing diagnosis,
or active problem list entry of “itching” were identified [3]. The comparison group was 1,039,167
pediatric patients without pruritus seen at JHHS over the same period. Each case of pruritus was also
subdivided into patients with or without a skin eruption (“eruption of skin”).
2.2. Pediatric Cancer Population
An EPIC Slicer Dicer was used to identify all pediatric patients with a diagnosed primary malignant
neoplasm (PMN). Malignancies were grouped by organ or organ system. Hematologic malignancies
were further delineated using disease specific diagnoses. Separately, patients were identified in whom
pruritus was diagnosed within the six months preceding their diagnosis of malignancy.
2.3. Statistical Analyses
Analyses compared instances of malignancy in pediatric patients with or without pruritus.
Additional analyses examined instances of pruritus in each malignancy. Sub analyses were performed
examining racial variation, age distribution, and the presence of concurrent kidney disease, liver disease,
hyperbilirubinemia, endocrine disorders and antineoplastic medication treatment. Microsoft Excel
(Redmond, WA, USA) was used to calculate odds ratios and 95% confidence intervals. Chi-squared
statistics with one degree of freedom were used to calculate odds ratio p-values. Z-tests were used to
calculate p-values for comparisons of odds ratios. To account for multiple comparisons, a Bonferroni
correction was applied to the alpha level for each analysis (alpha = 0.05/[number of independent
comparisons]).
3. Results
Between 2012 and 2019, a total of 1,042,976 pediatric patients were seen at JHHS. Demographic
data are presented in Table 1. The distribution of primary malignancies identified in the pediatric
hospital population is summarized in Figure 1.
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Table 1. Patient demographics.
All
(n = 1,042,976) n (%)

Itching
(n = 3836) n (%)

All PMNs
(n = 2980) n (%)

PMNs + Itching
(n = 130) n (%)

Male

542,125 (52)

1542 (40)

1571 (53)

65 (50)

Female

504,788 (48)

2302 (60)

1409 (47)

65 (50)

515,696 (49)

1348 (35)

1539 (52)

73 (56)

263,166 (25)

1771 (46)

567 (19)

27 (20) 3 of 9

51,847 (5)

202(5)

145 (5)

10 (8)

Characteristic
Sex

Race
White/Caucasian
Black/African
American
Medicines
2019, 6, 99
Asian

0–6
Age
Range

292,033 (28)

1151(30)

805 (27)

42 (32)

6–12
0–6

365,042
(35)
292,033
(28)

1458 (38)
1151(30)

1013(34)
805 (27)

43
(33)
42 (32)

6–12
12–18

365,042
(35)
385,901
(37)

1458
1228(38)
(32)

1013(34)
1162
(39)

43 (33)
45
(35)

12–18

385,901 (37)

1228 (32)

1162 (39)

45 (35)

Sex, race, and age distribution of the study population and study subgroups. Primary malignant
neoplasm (PMN).

Sex, race, and age distribution of the study population and study subgroups. Primary malignant neoplasm (PMN).
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3.1. Pruritus Is Strongly Associated with Malignancy in the Pediatric Population
3.1.
Pruritus2019
is Strongly
Associated
with Malignancy
in with
the Pediatric
Between
and 2012,
3809 pediatric
patients
itchingPopulation
were treated at JHHS of whom 130
were diagnosed
concomitant
Pediatric
with itching
significantly
more
Between with
2019 aand
2012, 3809malignancy.
pediatric patients
withpatients
itching were
treated were
at JHHS
of whom 130
were
diagnosed
with
a concomitant
Pediatric
itching were
likely
than
pediatric
patients
without malignancy.
a diagnosis of
itchingpatients
to havewith
malignancy
(OR significantly
12.84; 95% CI
more likely
pediatric
patients
without
a diagnosis
of itching
to have malignancy
(OR 12.84;of95%
10.73–15.35,
p <than
0.001)
(Figure
2). PMNs
strongly
associated
with pruritus
included neoplasms
bone
10.73–15.35,
< 0.001) (Figure
2). PMNs
associated
pruritus
neoplasms
of
(ORCI29.02;
95% CI p18.28–46.46,
p < 0.001),
skinstrongly
(OR 22.76,
95% CIwith
9.14–13.63,
p included
< 0.001), liver
(OR 21.55;
bone
(OR 29.02;p95%
CI 18.28–46.46,
< 0.001),
skin
(OR
95% CI 9.14–13.63,
< 0.001),hematologic
liver (OR
95%
CI 6.65–14.9,
< 0.001),
and bloodp (OR
14.38;
95%
CI22.76,
11.30–18.29,
p < 0.001). pAmong
21.55; 95%
CI 6.65–14.9,
< 0.001),associated
and bloodwith
(OR pruritus
14.38; 95%
CI 11.30–18.29,
p < 0.001).
Among
dyscrasias,
diagnoses
mostpstrongly
included
acute myeloid
leukemia
(OR
hematologic
dyscrasias,
diagnoses
most
strongly
associated
with
pruritus
included
acute
myeloid
23.14; 95% CI 14.64–36.56, p < 0.001), Hodgkin lymphoma (OR 12.35, 95% CI 6.08–25.11 p < 0.001),
leukemia (OR
23.14; 95%(OR
CI 14.64–36.56,
< 0.001),
Hodgkin
12.35,
95% CI 6.08–25.11
non–Hodgkin
lymphoma
10.48; 95%pCI
5.74–19.16,
p < lymphoma
0.001), and(OR
acute
lymphocytic
leukemia
p < 0.001), non–Hodgkin lymphoma (OR 10.48; 95% CI 5.74–19.16, p < 0.001), and acute lymphocytic
(OR 10.47; 95% CI 7.26–15.10, p < 0.001). The weakest association was observed for neoplasms of the
leukemia (OR 10.47; 95% CI 7.26–15.10, p < 0.001). The weakest association was observed for
nervous system (OR 1.26; 95% CI 2.13 5.70, p = 0.009), and eye (OR 2.87; 95% CI 0.40–20.61, p = 0.27).
neoplasms of the nervous system (OR 1.26; 95% CI 2.13 5.70, p = 0.009), and eye (OR 2.87; 95% CI 0.40–
No pruritus was observed in PMNs of the germ cells or biliary tract.
20.61, p = 0.27). No pruritus was observed in PMNs of the germ cells or biliary tract.

Medicines 2019, 6, 99
Medicines 2019, 6, 99

4 of 9
4 of 9

Figure
2. 2.Itching
malignancies.Odds
Odds
ratio
(OR)
with
95%
Figure
Itchingisisstrongly
strongly associated
associated with
with pediatric
pediatric malignancies.
ratio
(OR)
with
95%
confidence
interval
(95%
CI)
of
malignancy
in
patients
with
compared
to
without
itching
in
the
general
confidence interval (95% CI) of malignancy in patients with compared to without itching in the
pediatric
Blank rows
denote
for whichforthere
were
no concurrent
general hospital
pediatricpopulation.
hospital population.
Blank
rowsmalignancies
denote malignancies
which
there
were no
diagnoses
of
pruritus.
*
95%
CI
upper
limit
for
ENT
(159.2)
has
been
truncated.
•
= p• <= p0.001,
concurrent diagnoses of pruritus. * 95% CI upper limit for ENT (159.2) has been truncated.
<
chi-squared
test. Primary
malignant
neoplasm
(PMN).
0.001, chi-squared
test. Primary
malignant
neoplasm
(PMN).
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(30%)3).(Figure
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blood
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Figure 3.
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Figure
3. Prevalence
Lighter
bars
denote
the
percentage
of
patients
with
pruritus
and
a
primary
malignant
neoplasm
(PMN)
Lighter bars denote the percentage of patients with pruritus and a primary malignant neoplasm
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3.4. Pruritus Preceding Malignancy Is Associated with Hematologic Malignancy
3.4. Pruritus Preceding Malignancy is Associated with Hematologic Malignancy
Out of the total study population, 17 cases were identified in which a diagnosis of pruritus was
Out of the total study population, 17 cases were identified in which a diagnosis of pruritus was
made in the six months preceding a diagnosis of malignancy. Itch most often preadded PMNs of blood
made in the six months preceding a diagnosis of malignancy. Itch most often preadded PMNs of
(7/17, 41%) and the gastrointestinal tract (2/17, 12%). The most frequently-diagnosed hematologic
blood (7/17, 41%) and the gastrointestinal tract (2/17, 12%). The most frequently-diagnosed
neoplasms were leukemia (3/17, 18%) and non-Hodgkin lymphoma (3/17, 18%).
hematologic neoplasms were leukemia (3/17, 18%) and non-Hodgkin lymphoma (3/17, 18%).
3.5. Pruritus Among Pediatric Cancer Patients Is Associated with Comorbid Kidney Disease, Liver Disease,
3.5.
Among
Pediatric Cancer Patients is Associated with Comorbid Kidney Disease, Liver Disease,
and Pruritus
Antineoplastic
Use
and Antineoplastic Use
Analyses of pediatric patients with malignancy and itch found a statistically significant (p < 0.01)
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comorbidities in patients with pruritus within six months prior to their PMN diagnoses did not reach
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4. Discussion
4. Discussion
Pruritus is known to be associated with malignancies in adults, however limited data is available
Pruritus is known to be associated with malignancies in adults, however limited data is available
in the pediatric population [1,2]. While there have been sporadic pediatric cases of itch associated with
in the pediatric population [1,2]. While there have been sporadic pediatric cases of itch associated
diagnosed neoplasms, no large study has examined this association within a pediatric population [8–12].
with diagnosed neoplasms, no large study has examined this association within a pediatric
Our findings demonstrate associations between pruritus and malignancy in a diverse pediatric
population [8–12]. Our findings demonstrate associations between pruritus and malignancy in a
population at a USA tertiary care center.
diverse pediatric population at a USA tertiary care center.
Compared to pediatric patients without itch, pediatric patients with itch were 13 times more likely
Compared to pediatric patients without itch, pediatric patients with itch were 13 times more
to also be diagnosed with a malignancy (OR 12.84; 95% CI 10.73–15.35). By contrast, in a previous
likely to also be diagnosed with a malignancy (OR 12.84; 95% CI 10.73–15.35). By contrast, in a
study examining the association of itch and malignancy in the adult population, patients 18 years
previous study examining the association of itch and malignancy in the adult population, patients 18
or older with pruritus were approximately six times more likely to have concurrent malignancy as
years or older with pruritus were approximately six times more likely to have concurrent malignancy
compared to adult patients without pruritus (OR 5.76; 95% CI 5.53–6.00) [3].
as compared to adult patients without pruritus (OR 5.76; 95% CI 5.53–6.00) [3].
In the present study, the association of pruritus and malignancy was strongest for PMNs of bone,
In the present study, the association of pruritus and malignancy was strongest for PMNs of bone,
skin, liver, and blood, in particular, leukemia, non-Hodgkin and Hodgkin lymphoma. The association
skin, liver, and blood, in particular, leukemia, non-Hodgkin and Hodgkin lymphoma. The
was weakest amongst PMNs of the eye and nervous system. These findings somewhat differ from
association was weakest amongst PMNs of the eye and nervous system. These findings somewhat
those observed in adult patients with cancer. In the adult population, strong associations between itch
differ from those observed in adult patients with cancer. In the adult population, strong associations
and malignancy were observed in PMNs of liver, blood, and skin with weaker associations in PMNs of
between itch and malignancy were observed in PMNs of liver, blood, and skin with weaker
bone [3].
associations in PMNs of bone [3].
Previous publications have presented cases of pediatric patients with unexplained itch who upon
Previous publications have presented cases of pediatric patients with unexplained itch who
investigation were subsequently diagnosed with neoplasms such as Hodgkin lymphoma, Non-Hodgkin
upon investigation were subsequently diagnosed with neoplasms such as Hodgkin lymphoma, Nonlymphoma, T-cell lymphoma, and hepatocellular carcinoma [8–12]. In adults, pruritus has been
Hodgkin lymphoma, T-cell lymphoma, and hepatocellular carcinoma [8–12]. In adults, pruritus has
observed to most frequently proceed a hematologic malignancy or occasionally gastric cancers [15,16].
been observed to most frequently proceed a hematologic malignancy or occasionally gastric cancers
This study identified 17 pediatric patients with pruritus preceding their diagnoses of malignancy.
[15,16]. This study identified 17 pediatric patients with pruritus preceding their diagnoses of
Most often these pediatric pruritic patients were later diagnosed with hematologic neoplasms (7/17,
malignancy. Most often these pediatric pruritic patients were later diagnosed with hematologic
41%). Two instances of pruritus preceding gastric malignancy were also observed. These findings
neoplasms (7/17, 41%). Two instances of pruritus preceding gastric malignancy were also observed.
These findings suggest pediatric patients with itch and possible malignancy receive appropriate work
up for hematologic neoplasms.
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suggest pediatric patients with itch and possible malignancy receive appropriate work up for
hematologic neoplasms.
Subgroup analyses stratified by race revealed pronounced variation in the association of itch and
malignancy. However, further analyses revealed rates of pruritus in categorical malignancies were not
significantly different between races. The observed variation in association is therefore most likely due
to racial differences in malignancy rates and not due to racial differences in pruritus.
The pathophysiology of pruritus in malignancy remains poorly understood [15,17].
Multiple etiologies have been described including systemic inflammation, local mass effect,
antineoplastic medication use, and disruption of the hepatic or renal systems [15,18].
Hepatobiliary involvement may induce itch via accumulation of bile salts, bile acids, and bilirubin
or perhaps through increased opiodergic tone [15,18,19]. Kidney invasion, ureteric obstruction,
or renal failure meanwhile may induce uremic itch via the accumulation of pruritogenic metabolites
or possibly a cytokine imbalance [15]. With respect to the pathogenesis of pruritus in hematologic
malignancies, several mechanisms have been proposed. Previous studies have pointed to a possible
role of opioid receptors owing to the observed efficacy of butorphanol in reducing pruritus in a patient
with non-Hodgkin lymphoma [15,20]. Alternatively, variations in cytokine expression, known to be
increased in atopic dermatitis, have also been observed in patients with both Hodgkin and non-Hodgkin
lymphomas [15,21,22].
Compared to pediatric patients with malignancy but without itch, pediatric patients with PMNs
and pruritus were observed to have significantly higher prevalence of kidney disease, liver disease,
and antineoplastic medication use. Alternatively, patients with malignancy and itching with
skin eruption showed significantly increased prevalence of hyperbilirubinemia, kidney disease,
and antineoplastic use. These findings align with previously proposed mechanisms of pruritus
in malignancy [15,17,18]. Additional analyses are needed to determine if these comorbidities
developed as a direct result of a primary neoplastic process or secondary to antineoplastic use.
Furthermore, additional studies are needed to examine the specific qualities of pruritis in malignancies
and compare variation in itch intensity, location, and duration between different malignancy types.
Significant differences in pruritus rates were observed between malignancies of different systems
as well as between individual malignancy types. The reason for this variation is likely multifactorial
including differences in therapeutic management and effect on hepatic or renal processes [15,17,18].
With respect to hematologic malignancies, this observed variation may also be driven by differences in
cytokine expression [21–24]. Additionally, very few incidences of certain cancers including hairy cell
leukemia, multiple myeloma, and breast cancer were observed in our pediatric population which may
limit these findings.
Data were collected through a retrospective design therefore the cause–effect relationship of
these findings is limited. The tertiary care center population studied may limit the generalizability
of these findings to different populations. Additional unknown confounders such as differences in
socioeconomic level or other medical comorbidities could further limit these results.
5. Conclusions
In summary, our results indicate that pruritus is strongly associated with malignancy in the
pediatric population. Malignancies strongly associated included PMNs of bone, skin, liver, endocrine
glands, and blood. Additionally, several instances of itch preceding malignancy were identified.
To improve patient management and diagnosis, clinicians should recognize the high burden of itch in
pediatric malignancies and the variation in pruritus association across different malignancies.
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